Lachlan MacKinnon (L) and Adrian Woolfson (Replay)
Under hub-and-spoke biotech, serial founders launch new startup hoping to make gene therapies for the eye
In late July, Sangamo’s former R&D chief Adrian Woolfson, who left the biotech when it split its R&D, launched his own gene therapy outfit …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
